Journal of Sleep Disorders & Therapy
Open Access

Evaluating the effect of Obstructive Sleep Apnea (OSA) Treatment with CPAP on Menopause Rating Scale (MRS) among post-menopausal women

Amir Reihani^1*, Jacob P. VanHouten² and Vivek Jain^{3 *}Correspondence: Amir Reihani, Department of Medicine, Griffin Hospital, Derby, CT, USA, Tel: +1(203) 747 2266, Email:

Author info »

Introduction

Menopause is characterized by several changes in endogenous hormones due to a depletion of ovarian follicles [1]. It is accompanied by a significant decline in sex hormone levels, giving rise to distressing menopausal symptoms, including hot flashes, night sweats, mood disorders, sleep disturbances, urogenital disorders, bone loss, and metabolic problems. These can have a significant impact on the quality of life. The Study of Women's Health across the Nation (SWAN) [2] found that progression through the menopausal transition was associated with increasing self-reported sleep disturbances. Sleep disturbances during the menopause have been ascribed to several factors: physiological changes of aging, menopausal-related symptoms, stress, mood symptoms (e.g., depression and anxiety), and chronic health issues. Menopause is also associated with an independent risk for depression/depressive symptoms [3] that may impact sleep and quality of life.

Prevalence of another sleep disorder, obstructive sleep apnea (OSA), is increased after menopause [4,5]. OSA is characterized by recurrent collapses of the upper airway during sleep, and is associated with intermittent hypoxia, sleep fragmentation, surges of sympathetic tone, and oxidative stress, finally resulting in increased cardiovascular risk and excessive daytime sleepiness [5-7]. In the general population, OSA treatment with continuous positive airway pressure (CPAP) is associated with improvement in daytime sleepiness and quality of life [8]. However, the impact of OSA treatment on post-menopausal symptoms, including depression and daytime sleepiness, is not known.

The Menopause Rating Scale (MRS) is a standardized, reliable, and validated self-administered scale used to evaluate the severity of symptoms over time, and assess quality of life in post-menopausal women [9]. We hypothesized that treatment of OSA with CPAP in postmenopausal women would lead to improvements in MRS scores, in addition to having an impact on depression and excessive daytime sleepiness in this population.

Methods

We conducted a prospective, cohort study in post-menopausal women with moderate to severe newly diagnosed OSA presenting to the George Washington University (GW) Medical Faculty Associates Center for Sleep Disorders. Participants were approached for participation at the time of diagnosis by polysomnography. Data were collected by the authors via questionnaire at initial and subsequent visits. Patients were consented only if they had opted for CPAP for the treatment of sleep apnea. Baseline Epworth sleepiness scale (ESS), Menopausal Rating Scale (MRS) scores and Hamilton rating scale (HAM-D) for depression were obtained prior to starting CPAP therapy and again after 3 months on a followup visit, when a compliance download of their CPAP use was also obtained. Written informed consent was obtained from all patients before enrollment. The study was approved by The George Washington University Institutional Review Board (IRB#031209).

All women above the age of 42 years who were menopausal were eligible to participate. Only women with no self-reported menses for greater than one year were defined as menopausal and considered eligible for participating in the study. Women who have regular menstruation (defined as cycles that vary in length by no more than five days and vary in interval between 23 and 35 days) were defined as premenopausal and excluded from the study. Women with irregular menstrual cycles (defined as cycles lasting <23 days or >35 days or varying by more than five days) or with no menstrual bleeding for less than one year were defined as peri-menopausal and also excluded. We did not exclude women if they were actively taking hormone replacement therapy or antidepressants. However, we excluded patients who were diagnosed with major depression that had initiated a new antidepressant medication or switched to a different dose of their usual antidepressant within six months, or during this study period.

All participants had been diagnosed with moderate to severe sleep apnea based on the results of an in-lab polysomnography (PSG) conducted at The Center for Sleep Disorders at the Medical Faculty Associates at The George Washington University. The PSG was conducted using a Respironics Alice 6 LDXN Sleep Diagnostic System (Philips Respironics, Murrysville, PA). A standard set of clinical measurements were acquired during the PSG, including the ECG, EEG, oxyhemoglobin saturation, and respiratory airflow. Registered polysomnographic technologists (RPSGT) manually scored the PSG data, including identification of sleep stages, apneic and hypopneic events, and arousals using standard criteria [10]. Hypopnea was defined as a reduction in ventilation of greater than 30% that lasted for at least 10 seconds and resulted in a decrease in arterial saturation of 4% or more [10]. Apnea was defined as a reduction in the peak signal excursion of greater than 90% and lasting at least 10 seconds. The severity of OSA was defined by the apnea-hypopnea index (AHI) (total number of apneas and hypopneas during the study divided by the hours of sleep). An AHI of <5/hr is normal; AHI between 5-15/hr is mild disease; AHI between 15-30/hr is moderate and AHI >30/hr is severe disease [11].

Baseline demographic data was obtained from all participants, including age, race and body mass index (BMI). In addition, the participants completed the ESS, MRS, and HAM-D at baseline, and again on follow-up visit.

The Epworth Sleepiness Scale (ESS) is a self-administered questionnaire with 8 questions. Respondents are asked to rate, on a 4-point scale (0-3), their usual chances of dozing off or falling asleep while engaged in eight different activities. Most people engage in those activities at least occasionally, although not necessarily every day. The ESS score (the sum of 8 item scores, 0-3) can range from 0 to 24. The higher the ESS score, the higher that person’s average sleep propensity in daily life (ASP), or their ‘daytime sleepiness’. The questionnaire takes no more than 2 or 3 minutes to answer.

Psychometric properties of the ESS have been extensively investigated. The internal consistency of responses to the eight questions has been tested by Cronbach’s alpha (mean=0.82) in multiple investigations [12,13].

The Menopause Rating Scale (MRS) is a questionnaire evaluating the severity of 11 symptom categories related to menopause on a scale from 0 (no symptoms) to 4 (extremely severe). These include such symptoms as hot flashes, heart discomfort, trouble sleeping, depressive feelings, irritability, sexual problems, vaginal dryness, mental and physical exhaustion, joint and muscular pain, and more. Women assign a number next to each of the eleven symptoms identified on the questionnaire. The total score of the MRS ranges between 0 (asymptomatic) and 44 (highest degree of complaints) [14]. The reliability and validity of the MRS are well-studied in extensive multinational surveys in 2001-2002. Reliability measures were found to be acceptable across nine countries. Cronbach’s alpha ranged between 0.8 and 0.96 across Europe, North and Latin America, and Asia [15].

The Hamilton Depression Rating Scale (HAM-D) is the most widely used clinician-administered depression assessment scale. It is a multiple item questionnaire used to provide an indication of depression, and as a guide to evaluate recovery. A score of 0-7 is considered normal, 8-13 (mild) 14-18 (moderate), 19-22 (severe), and >23 (very severe) depression. The validity of the HAM-D has been repeatedly investigated in general populations. Bagby et al. performed a comprehensive review and collogues examined the psychometric properties of the HAM-D in 70 published studies [16]. The results of their investigation found acceptable internal consistency and discriminant validity. Cronbach’s alpha (mean=0.70) [16].

We defined CPAP compliance per the Center for Medicare and Medicaid Services (CMMS) guidelines, where use of CPAP device for at least 4 hours a night on at least 70% of the nights is considered compliant. Compliance download was obtained from the subject’s CPAP unit at the time of the follow-up visit. Analyses were conducted using R v4.0.2 (RCore Team, Austria 2020) [17]. Descriptive statistics were calculated as medians and IQR of continuous variables due to an assumption of nonnormality, and frequencies reported for categorical variables.

Sample Characteristics

Baseline characteristics are listed in Table 1. During the recruitment period, post-menopausal women underwent polysomnography and were diagnosed with moderate to severe sleep apnea. During the initial visit 49 women met eligibility criteria for the study. Among the participants, 19 women were excluded because either did not start CPAP treatment or they did not have time to participate. A total of 30 women provided informed consent and completed baseline questionnaires for the study. A further eight women were excluded either because they were noncompliant with their treatment or because we were unable to verify their compliance by data. Ultimately, 22 women from the initial cohort included in the final analysis (Figure 1).

Table 1: Baseline characteristics of study population.

Table 2: ESS, HAM-D, and MRS at initiation and first return visit.

Figure 1: Data Collection Process.

There was a range of baseline apnea severity, but the average AHI was in the moderate range (median 30.8, IQR 17.5-71.1). Median subjective sleepiness was 8 (IQR 4-12) and median BMI was in the obese range at 32.5 (IQR 29.0-37.6). Hamilton Rating Scale for Depression (HAM-D) was measured at baseline for each participant. Median HAM-D was 7 (IQR 5-11) where a score of less than 7 is considered normal. Median Menopausal Rating Scale (MRS) was 15 (IQR 9.5-19.0), with MRS<4 defined as little or no menopausal symptoms, 5-8 mild; 9-15 Moderate; 16+ Severe.

Association between CPAP Compliance and Outcomes

Improvement in symptoms after CPAP use

Return visit occurred 158 (IQR 117-223) days after the initial visit. There was a statistically significant improvement of 6.5 points on MRS for this patient population from diagnosis to this follow up visit. There was also an improvement in HAM-D which did not reach significance at α=0.05 level, but which was significant at α=0.10 level. The associated p-values for ESS, HRSD, and MRS were p=0.1129, 0.0762, 0.0007, respectively.

While not a primary purpose of this study, further sub-analysis by baseline AHI and by race (coded as Caucasian vs non-Caucasian) revealed no effect of these variables on ESS, HAM-D, or MRS (data not shown).

Discussion

Our findings demonstrate that post-menopausal women with OSA can derive substantial improvement in their menopauserelated symptoms separate from an independent effect on daytime sleepiness or depression when treated with CPAP. Although those effects did not reach significance at the α=0.05 level, there is still weak suggestion that depression may also be improved independent of improvement in sleepiness symptoms.

As life expectancy increases, women will spend more than onethird of their lives postmenopausal. Good health in old age is critical for both individual women and the whole society. Unfortunately, this transition to menopause is also associated with vasomotor symptoms, sexual dysfunction, mood changes and sleep disturbances that significantly impact quality of life. Sleep disturbances during the menopause have been ascribed to several factors, including physiological changes of aging, menopausalrelated symptoms, stress, mood symptoms (e.g. depression and anxiety), and chronic health issues. Whether sleep problems during the menopausal years are the result of interrupted sleep due to vasomotor symptoms (VMS) or whether they are separate entities is still unclear.

Post-menopausal symptoms have been traditionally treated with hormonal replacement therapy (HRT)[18], but HRT is associated with increased risk of side effects, including deep venous thrombosis and breast cancer [19]. Use of HRT has therefore declined over the years [20]. In light of this, our findings of improved postmenopausal symptoms in women with OSA treated with CPAP is of increased significance and interest, as it may offer an alternative non-HRT based therapy to improve menopausal symptoms in menopausal women with OSA.

OSA prevalence is increased in post-menopausal women, with studies suggesting a prevalence of 45.2% for mild to moderate OSA and 10.1% for severe OSA (AHI>30) [4] in contrast to the general population, where the prevalence of OSA has been reported to be 22% among men and 7% among women [21]. It is believed that the decline in sex hormones, especially estrogen, is the likely etiology [22]. OSA presents differently depending on gender, and is under recognized as women may not present with classic OSA symptoms of loud snoring, choking sensations and excessive daytime sleepiness. Women with OSA often complain of insomnia, fatigue, headache, mood disorders and lack of energy [20,23]. Therefore, it is not surprising that the ESS was within normal limits in our cohort of post-menopausal women with moderate to severe OSA. Based on our findings, we propose that clinicians and healthcare providers caring for post-menopausal women should have a higher index of suspicion and low threshold for ruling out sleep apnea in this population.

Cross-sectional and prospective studies have investigated a potential association between menopause and the risks for depressive symptoms or new onset or recurrent major depressive disorder (MDD) [24]. Data from cross-sectional studies indicate that depressive symptoms might be endorsed by up to 70% of women during perimenopause compared with around 30% in premenopausal years [25]. Studies in non-menopausal populations have shown an association between OSA and depression [26], with improvement with CPAP treatment [27]. Our data revealed a trend in improvement in depression scores (as measured by HAM-D) with CPAP treatment. Our cohort included women on antidepressants, thus emphasizing the need for ruling out OSA in this population, perhaps masquerading as depression.

Conclusion

Our findings demonstrate strong evidence of an improvement in menopausal symptoms in post-menopausal women with OSA treated with CPAP, independent of an effect on sleepiness or depressive symptoms. Additional clinical trials are needed to affirm these results in a larger population of menopausal women with OSA, to determine the efficacy of long-term treatment, and to garner a better understanding of the pathophysiologic mechanisms linking OSA with post-menopausal symptoms.

Conflict of Interest

All authors report no conflict of interest. The authors alone are responsible for the content and writing of this paper.

References

1. Shifren JL, Gass MLS, Kagan R, Kaunitz AM, Liu JH, Pinkerton JA V., et al. The North American Menopause Society recommendations for clinical care of midlife women. Menopause. 2014;21(10):1038–1062.
2. Kravitz HM, Zhao X, Bromberger JT, Gold EB, Hall MH, Matthews KA, et al. Sleep disturbance during the menopausal transition in a multi-ethnic community sample of women. Sleep. 2008;31(7):979-990.
3. Bromberger JT, Kravitz HM. Mood and Menopause: Findings from the Study of Women’s Health Across the Nation (SWAN) over 10 Years. Obstet Gynecol Clin North Am. 2011;38(3):609–25.
4. Heinzer R, Marti-Soler H, Marques-Vidal P, Tobback N, Andries D, Waeber G, et al. Impact of sex and menopausal status on the prevalence, clinical presentation, and comorbidities of sleep-disordered breathing. Sleep Med [Internet]. 2018;51:29-36.
5. Hung J, Whitford EG, Parsons RW, Hillman DR. Association of sleep apnoea with myocardial infarction in men. Lancet (London, England). 1990;336(8710):261-264.
6. Dhillon S, Chung SA, Fargher T, Huterer N, Shapiro CM. Sleep apnea, hypertension, and the effects of continuous positive airway pressure. Am J Hypertens. 2005;18(5):594-600.
7. Tilkian AG, Guilleminault C, Schroeder JS, Lehrman KL, Simmons FB, Dement WC. Hemodynamics in sleep-induced apnea. Studies during wakefulness and sleep. Ann Intern Med. 1976;85(6):714–9.
8. Batool-Anwar S, Goodwin JL, Kushida CA, Walsh JA, Simon RD, Nichols DA, et al. Impact of continuous positive airway pressure (CPAP) on quality of life in patients  with obstructive sleep apnea (OSA). J Sleep Res. 2016;25(6):731-738.
9. Schneider HP, Heinemann LA, Rosemeier HP, Potthoff P, Behre HM. The Menopause Rating Scale (MRS): reliability of scores of menopausal complaints. Climacteric. 2000;3(1):59-64.
10. Bazzano LA, Khan Z, Reynolds K, He J. Effect of nocturnal nasal continuous positive airway pressure on blood pressure in  obstructive sleep apnea. Hypertens (Dallas, Tex 1979). 2007;50(2):417-423.
11. Flemons WW, Buysse D, Redline S, Oack A, Strohl K, Wheatley J, et al. Sleep-related breathing disorders in adults: Recommendations for syndrome definition and measurement techniques in clinical research. Sleep. 1999;22(5):667-689.
12. Johns MW. Reliability and factor analysis of the Epworth Sleepiness Scale. Sleep. 1992 Aug;15(4):376-381.
13. Hagell P, Broman J-E. Measurement properties and hierarchical item structure of the Epworth Sleepiness  Scale in Parkinson’s disease. J Sleep Res. 2007;16(1):102-109.
14. Hauser GA, Huber IC, Keller PJ, Lauritzen C, Schneider HP. [Evaluation of climacteric symptoms (Menopause Rating Scale)]. Zentralbl Gynakol. 1994;116(1):16-23.
15. Bagby RM, Ryder AG, Schuller DR, Marshall MB. The Hamilton Depression Rating Scale: has the gold standard become a lead weight? Am J Psychiatry. 2004;161(12):2163-2177.
16. Heinemann LAJ,DoMinh T,Strelow F, Gerbsch S, Schnitker J, Schneider HPG. The Menopause Rating Scale (MRS) as outcome measure for hormone treatment? A validation study.Health and Quality of Life Outcomes. 2004;2:67.
17. Computing RF for S. R: A language and environment for statistical computing. [Internet]. Vienna, Austria.: R Core Team; 2020. Available from: https://www.r-project.org/.
18. Collins Fantasia H, Sutherland MA. Hormone therapy for the management of menopause symptoms. J Obstet Gynecol neonatal Nurs  JOGNN. 2014;43(2):226-229.
19. Lobo RA. Hormone-replacement therapy: current thinking. Nat Rev Endocrinol. 2017 Apr;13(4):220-231.
20. Valipour A, Lothaller H, Rauscher H, Zwick H, Burghuber OC, Lavie P. Gender-related differences in symptoms of patients with suspected breathing  disorders in sleep: a clinical population study using the sleep disorders questionnaire. Sleep. 2007;30(3):312-319.
21. Theorell-Haglöw J, Miller CB, Bartlett DJ, Yee BJ, Openshaw HD, Grunstein RR. Gender differences in obstructive sleep apnoea, insomnia and restless legs syndrome in adults - What do we know? A clinical update. Sleep Med Rev. 2018;38:28-38.
22. Perger E, Mattaliano P, Lombardi C. Menopause and Sleep Apnea. Maturitas. 2019;124:35-38.
23. Cairns, G. Poulos, R. Bogan, A. Cairns, G. Poulos RB. Sex differences in sleep apnea predictors and outcomes from home sleep apnea testing. Nat Sci Sleep. 2016;8:197-205.
24. Bromberger, J.; Kravitz H. Mood and Menopause: Findings from the Study of Women’s Health Across the Nation (SWAN) over ten years. Obs Gynecol Clin North Am. 2011;38(3):609-625.
25. Bromberger JT, Schott L, Kravitz HM. Risk factors for major depression during midlife among a community sample of women with and without prior major depression: are they the same or different? Psychol Med. 2015;45:1653-1664.
26. Jackson ML, Tolson J, Bartlett D, Berlowitz DJ, Varma P, Barnes M. Clinical depression in untreated obstructive sleep apnea: examining predictors and a meta-analysis of prevalence rates. Sleep Med. 2019;62:22-28.
27. Gupta MA, Simpson FC. Obstructive sleep apnea and psychiatric disorders: a systematic review. J Clin sleep Med  JCSM  Off Publ Am  Acad Sleep Med. 2015;11(2):165-175.